A carregar...
Risk of cumulative toxicity after complete melanoma response with pembrolizumab
Pembrolizumab is an approved first-line systemic therapy for unresectable metastatic melanoma. Despite the achievement of complete and durable responses in a small subgroup of patients, it is standard practice that pembrolizumab therapy continues beyond complete response. Nevertheless, the incidence...
Na minha lista:
| Publicado no: | BMJ Case Rep |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5294005/ https://ncbi.nlm.nih.gov/pubmed/28148549 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2016-218308 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|